MarketPeel
Insider Trading Intelligence
PC

Pamela Ann Connealy

PYXS
CFO AND COO · PYXIS ONCOLOGY, INC. · CIK 0001796310
FILING MIX · LIFETIME90%/10%
BUYS
35
SELLS
4
TOTAL VALUE
$687.5K
COMPANIES
3
ACTIVE SINCE
May 2020
HOLDINGS NOW
526,401
AVG SELL PX
$1.40
TRADE KIND
SHOWING 39 / 39
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 2 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Pamela Ann Connealy, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%+8.51%-0.33%+8.84%+5.67%
14d6+50.00%+7.01%+0.69%+6.32%+1.78%
30d6+0.00%-11.08%-2.10%-8.98%-8.93%
60d6+0.00%-13.76%+4.42%-18.17%-17.10%
90d6+16.67%-13.88%+7.26%-21.13%-21.94%
180d6+66.67%+81.44%+13.69%+67.75%+70.65%
1y6+100.00%+134.85%+27.81%+107.05%+82.55%
2y6(2 pending)+100.00%+19.68%+57.50%-37.82%-38.12%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PYXS · 414,163 shares · as of Mar 31, 2025
0299,786599,572899,3571,199,1432022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 35 buys / 4 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
17,32766,038Jun 23, 2026Jun 25, 2026View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
21,27721,277Jun 23, 2026Jun 25, 2026View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
15,00048,711Aug 7, 2025Aug 8, 2025View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
12,42233,711Jun 24, 2025Jun 26, 2025View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
36,79736,797Jun 24, 2025Jun 26, 2025View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
414,163$0.98$405.9K414,163Mar 31, 2025Apr 2, 2025View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
310,000310,000Dec 23, 2024Dec 23, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO & COO
83,400$1.96$163.5K1,199,143Nov 26, 2024Nov 27, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO & COO
5,450$2.00$10.9K1,115,743Nov 26, 2024Nov 27, 2024View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
5,37621,289Jun 20, 2024Jun 21, 2024View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
17,06817,068Jun 20, 2024Jun 21, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
328,7101,110,293Mar 26, 2024Mar 28, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
SALE
CFO and COO
36,949$1.40$51.7K781,583Nov 29, 2023Nov 30, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO and COO
8,000$1.87$15.0K818,532Sep 28, 2023Sep 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO and COO
6,426$1.85$11.9K810,532Sep 27, 2023Sep 27, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO and COO
12,000$1.67$20.0K804,106Sep 25, 2023Sep 25, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
CFO and COO
5,000$1.74$8.7K792,106Sep 22, 2023Sep 22, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
187,793782,106Sep 7, 2023Sep 8, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Jul 20, 2023Jul 24, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,66715,913Jul 20, 2023Jul 24, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASE
7584,246Apr 12, 2023May 5, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
SALE
758758Apr 12, 2023May 5, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
209,803594,313Mar 24, 2023Mar 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
322,265322,265Mar 24, 2023Mar 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
SALE
CFO and COO
10,3040Mar 24, 2023Mar 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
10,30410,304Mar 24, 2023Mar 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
SALE
CFO and COO
322,2650Mar 24, 2023Mar 28, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
3,4883,488Jan 26, 2023Jan 30, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
1,5161,516Jan 26, 2023May 5, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
23,25023,250Jan 26, 2023May 19, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
23,25023,250Jan 26, 2023Jan 30, 2023View →
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
PURCHASEGRANT
Stock grant
18,60018,600Jan 26, 2023Jan 30, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
43,493384,510Jan 3, 2023Jan 3, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
93,493341,017Apr 14, 2022Apr 15, 2022View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
247,524247,524Mar 31, 2022Apr 4, 2022View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
52,94452,944Dec 6, 2021Dec 7, 2021View →
IMVT
IMMUNOVANT, INC.
PURCHASEGRANT
Stock grant
162,000162,000Mar 19, 2021Mar 23, 2021View →
IMVT
IMMUNOVANT, INC.
PURCHASEGRANT
Stock grant
46,20046,200Mar 19, 2021Mar 23, 2021View →
IMVT
IMMUNOVANT, INC.
PURCHASEGRANT
Stock grant
180,500180,500May 15, 2020May 18, 2020View →
Other insiders · PYXS
Loading peer insiders…
About this filer
CIK 0001796310
ROLE
CFO and COO
PRIMARY
PYXS
COMPANIES
3
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001796310DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback